Email response
2 to 4%
Industry lead generation
Biotechnology & Genomics lead generation.
6+ biotech clients trust CIENCE: including Phase Genomics, Psomagen, and Igenomx.
Industry KPI dashboard
CAC, ACV, conversion, cycle
01
CAC range
18 to 28%
02
Typical ACV
$80,000
03
Meeting to close
5%
04
Sales cycle
16 to 32 weeks
01 / Landscape
Biotechnology & Genomics customer acquisition has its own physics.
The global biotechnology market exceeds $1.3 trillion, with genomics, proteomics, and bioinformatics driving rapid growth across research, clinical diagnostics, and drug development. Selling into biotech requires a fundamentally different approach than traditional B2B: your buyers are scientists who evaluate vendors with the same rigor they apply to peer-reviewed research.
Sales cycles in biotechnology run 16-32 weeks, among the longest in B2B, because of the validation rigor involved. Prospects need to evaluate data quality, run pilot analyses, check publication citations, and navigate grant or institutional procurement processes. The 5% meeting-to-close rate reflects this selectivity, but the high typical ACV of $80,000 makes each conversion extremely valuable.
CIENCE has built pipeline for biotechnology companies including Phase Genomics (proximity ligation), Psomagen (microbiome sequencing), Second Genome (microbiome therapeutics), and Igenomx (immune repertoire sequencing). Our campaigns combine scientific credibility with SDR expertise to reach researchers, lab directors, and biotech executives.
02 / Channels
Benchmarks from the source industry model.
Phone connect
3 to 5%
LinkedIn engagement
6 to 12%
Best channel logic
Email with scientific content: biotech buyers are researchers and scientists who evaluate vendors based on peer-reviewed evidence, technical specifications, and data quality. Email sequences that include white papers, application notes, and published research results significantly outperform generic outreach. Conference follow-up is also critical.
03 / GTM challenges
Why generic outbound underperforms here.
Biotech buyers are PhD-level scientists who dismiss non-technical outreach immediately: SDRs must demonstrate genuine understanding of genomics workflows, sequencing platforms, and bioinformatics pipelines to earn credibility
Sales cycles of 16-32 weeks reflect the rigorous validation process in life sciences: prospects require technical demonstrations, sample data analysis, and peer publication reviews before procurement approval
Grant funding cycles dictate purchasing timelines: NIH, NSF, and private foundation grant awards create specific buying windows that are missed if outreach timing isn't aligned to funding announcements
Regulatory considerations (FDA, EMA, CLIA/CAP for clinical labs) add compliance layers to every purchasing decision: vendors must demonstrate regulatory pathway support, not just technical capability
04 / Source case studies
Proof patterns named in the source page.
01
Phase Genomics
Challenge
Needed to build pipeline for their proximity ligation and Hi-C sequencing services targeting academic researchers and pharmaceutical R&D teams
Result
Generated qualified meetings with principal investigators and R&D directors at target research institutions and pharma companies
02
Psomagen
Challenge
Required outbound pipeline generation for their microbiome sequencing and bioinformatics services in a rapidly growing but technically complex market
Result
Built consistent pipeline of qualified meetings through scientifically credible outreach targeting microbiome researchers and clinical labs
03
Igenomx
Challenge
Needed to reach immunology researchers and clinical diagnostics labs for their immune repertoire sequencing platform
Result
Generated pipeline with immunology labs and clinical diagnostics facilities through targeted campaigns emphasizing research applications and clinical utility
05 / Buyer personas
Message by role, pain, and channel.
01
Principal Investigator / Lab Director
Lead with scientific application relevance: reference specific research applications (metagenomics, epigenomics, immune profiling) and show published data demonstrating your platform's performance on comparable sample types.
EmailLinkedIn
01 Grant budgets are tight and every technology purchase must directly advance publication-worthy research outcomes
02 Current sequencing vendor's turnaround times are 6-8 weeks, delaying publication timelines and grant milestone reporting
03 Bioinformatics analysis is the bottleneck: generating sequencing data is easy but interpreting it requires computational resources the lab doesn't have
02
VP of R&D / CSO
Focus on validation data and regulatory pathway support: show how your platform has been used in FDA submissions, clinical trials, or CLIA-certified workflows. Pharma R&D buyers need to see regulatory acceptance, not just technical performance.
EmailLinkedInPhone
01 Drug development pipeline depends on biomarker discovery and target validation: delays in genomic analysis directly slow clinical timelines
02 Need to evaluate new platforms but validation studies require 3-6 months of parallel testing against existing methods
03 Regulatory submission requirements demand validated, reproducible analytical methods: switching platforms creates regulatory risk
03
Director of Clinical Diagnostics
Lead with clinical validation and regulatory compliance: demonstrate CLIA/CAP pathway, published clinical utility data, and reimbursement precedents for your testing platform.
EmailPhone
01 CLIA/CAP accreditation requirements constrain which platforms and assays can be used for clinical testing
02 Reimbursement uncertainty for genomic tests makes it difficult to justify new platform investments without clear payer coverage pathways
03 Sample volume is growing faster than laboratory capacity: need higher throughput without compromising quality or compliance
06 / CIENCE approach
How CIENCE builds pipeline for Biotechnology & Genomics.
As a graph8 company, CIENCE uses AI to identify biotech organizations actively investing in new research capabilities. The graph8 platform monitors NIH and NSF grant awards, clinical trial registrations, scientific publication patterns, and hiring signals for research scientists: all indicators that a lab, biotech company, or research institution is entering a technology procurement cycle.
For biotechnology specifically, we deploy SDRs with life sciences backgrounds from our Talent Cloud. These SDRs understand the difference between short-read and long-read sequencing, can discuss metagenomics workflows, and know which applications require CLIA-certified processes. Campaigns include scientific application notes and published data rather than marketing collateral, because biotech buyers evaluate evidence, not brochures.
Tenbound, our sister brand for sales development research, provides benchmark data on life sciences buyer engagement patterns: including the critical role of scientific conferences (ASHG, AGBT, AACR) in the biotech purchasing journey and how to optimize pre-conference and post-conference outreach sequences.
FAQ
Biotechnology & Genomics lead generation.
01
How much does biotech lead generation cost?
Biotech lead generation targets a CAC-to-ACV ratio of 18-28%. With typical contract values around $80,000, that means a target CAC of $14,400-$22,400. While this CAC is higher than many verticals, the high ACV and strong retention rates in biotech make the unit economics compelling.
02
How long do biotech sales cycles take?
Biotechnology sales cycles run 16-32 weeks: among the longest in B2B: due to scientific validation requirements, pilot studies, and grant-aligned procurement. CIENCE campaigns are designed for this extended timeline with science-driven nurture sequences. Meeting-to-close rates average 5%.
03
Can CIENCE SDRs handle scientific conversations?
Yes. Our Talent Cloud includes SDRs with life sciences backgrounds who understand genomics workflows, sequencing platforms, bioinformatics pipelines, and regulatory frameworks like CLIA/CAP. They can engage credibly with PIs, lab directors, and R&D executives.
04
What biotech companies has CIENCE worked with?
CIENCE has generated pipeline for biotech companies including Phase Genomics (Hi-C sequencing), Psomagen (microbiome sequencing), Second Genome (microbiome therapeutics), and Igenomx (immune repertoire sequencing). Our graph8 AI platform identifies labs and biotech companies entering buying cycles based on grant awards and research signals.
05
How does CIENCE align campaigns to grant funding cycles?
The graph8 platform monitors NIH, NSF, and private foundation grant awards in real time. When a target lab receives funding for research that requires your technology, our campaigns reach them during the procurement window: typically 30-90 days after award notification when purchasing decisions are being made.
Related industries
Explore adjacent verticals.
Industry
Healthcare & Life Sciences
9+ healthcare clients trust CIENCE: including BetterHelp and Covance
IndustryManufacturing & Industrial
8+ manufacturing clients trust CIENCE: including Yamaha and Beijer Electronics
IndustryAI & Machine Learning
9+ AI clients trust CIENCE: including Symbl.ai, Diffbot, and DataWeave
Industry pipeline plan
Ready to build pipeline in Biotechnology & Genomics?
CIENCE combines graph8 data, trained SDR capacity, and Tenbound research so this industry motion has the right buyer, message, and channel from the start.